PE majors eye Orbicular Pharma stake, valuation seen up to $1.5 bn

Private equity firms such as Warburg Pincus and CVC Capital Partners have evinced interest in Orbicular Pharma as the specialty pharma firm explores a stake sale in a deal that will likely value the company up to $1.5 billion.